Evidence map›Paper›PMID 38357683›Full record

ArticleCase reports in oncology

Occurrence of Fatal Tubulopathy in an Old, Fit Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report.

Marine Georgery, Aurélie Ram, Tess Van Meerhaeghe, Annie Drowart, Anne-Lorraine Clause, Lissandra Dal Lago, Héloïse Rouvière

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Marine GeorgeryDepartment of Geriatric Medecine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Aurélie RamDepartment of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Tess Van MeerhaegheDepartment of Nephrology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Annie DrowartDepartment of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Anne-Lorraine ClauseDepartment of Nephrology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Lissandra Dal LagoDepartment of Medical Oncology, CHIREC, Brussels, Belgium.
Héloïse RouvièreDepartment of Geriatric Medecine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Université Libre de Bruxelles · BECentre Hospitalier Interrégional Edith Cavell · BEErasmus Hospital · BEInstitut Jules Bordet · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The use of immune checkpoint inhibitors has revolutionized cancer treatment, and their application to older people is considered safe by the scientific community. However, immune-related adverse events (irAEs) remain common, and their management poses significant challenges, especially in this population. Case Presentation: We report the case of a fit 82-year-old woman who developed immune-mediated colitis and Fanconi syndrome during treatment with ipilimumab and nivolumab for metastatic melanoma. Treatment consisted of discontinuation of immunotherapy, use of systemic corticosteroids, and second-line immunosuppressants. Despite well-managed treatment, the patient did not recover and died from a gastrointestinal infection. Conclusion: Although studies have shown identical efficacy and safety in younger patients compared to older patients, the consequences of irAEs can potentially be more serious in the older population. The fatal outcome despite well-managed treatment highlights the need to identify predictive factors of immunotherapy-related adverse events in the older population.

Indexed as

Case reportElderlyFanconi syndromeImmune checkpoint inhibitorsMelanoma

Identifiers

PMID38357683
PMCPMC10866611
OpenAlexW4391806022

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.